Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2001 Sep;78(3):550–567. doi: 10.1093/jurban/78.3.550

Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program

David C Perlman 1,✉, Marc N Gourevitch 2, Chau Trinh 1, Nadim Salomon 1, Leslie Horn 1, Don C Des Jarlais 1
PMCID: PMC3455907  PMID: 11564856

Abstract

This study examined whether costs associated with tuberculosis (TB) screening and directly observed preventive therapy (DOPT) among drug injectors attending a syringe exchange are justified by cases and costs of active TB cases prevented and examined the impact of monetary incentives to promote adherence on cost-effectiveness. We examined program costs and projected savings using observed adherence and prevalence rates and literature estimates of isoniazid (INH) preventive therapy efficacy, expected INH hepatoxicity rates, and TB treatment costs; we conducted sensitivity analyses for a range of INH effectiveness, chest X-ray (CXR) referral adherence, and different strategies regarding anergy among persons affected with human immunodeficiency virus (HIV). For 1,000 patients offered screening, incorporating real observed program adherence rates, the program would avert $179,934 in TB treatment costs, for a net savings of $123,081. Assuming a modest risk of TB among HIV-infected anergic persons, all strategies with regard to anergy were cost saving, and the strategy of not screening for anergy and not providing DOPT to HIV-infected anergic persons resulted in the greatest cost savings. If an incentive of $25 per person increased CXR adherence from the observed 31% to 50% or 100%, over a 5-year follow-up the net cost savings would increase to $170,054 and $414,856, respectively. In this model, TB screening and DOPT at a syringe exchange is a cost-effective intervention and is cost-saving compared to costs of treating active TB cases that would have occurred in the absence of the intervention. This model is useful in evaluating the cost impact of planned program refinements, which can then be tested. Monetary incentives for those referred for screening CXRs would be justified on a cost basis if they had even a modest beneficial impact on adherence.

Full Text

The Full Text of this article is available as a PDF (139.8 KB).

References

  • 1.Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Int Med. 1979;139:337–339. doi: 10.1001/archinte.139.3.337. [DOI] [PubMed] [Google Scholar]
  • 2.Perlman D, Salomon N, Perkins MP, Yancovitz S, Paone D, Jarlais DC. Tuberculosis in drug users. Clin Infec Dis. 1995;21:1253–1264. doi: 10.1093/clinids/21.5.1253. [DOI] [PubMed] [Google Scholar]
  • 3.Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–550. doi: 10.1056/NEJM198903023200901. [DOI] [PubMed] [Google Scholar]
  • 4.Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res. 1969;17:28–106. [PubMed] [Google Scholar]
  • 5.International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO. 1982;60:555–564. [PMC free article] [PubMed] [Google Scholar]
  • 6.Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935–943. doi: 10.1164/arrd.1967.95.6.935. [DOI] [PubMed] [Google Scholar]
  • 7.Wadhawan D, Hira S, Mwanasa N, Tembo G, Perine PL. Preventive tuberculosis chemotherapy with isoniazid among persons infected with HIV-1. In: Ninth International Conference on AIDS; June 6–11, 1993; Berlin, Germany. Abstract PO-BO7-1114.
  • 8.Pape JJW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268–272. doi: 10.1016/0140-6736(93)91817-6. [DOI] [PubMed] [Google Scholar]
  • 9.Whalen C, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801–808. doi: 10.1056/NEJM199709183371201. [DOI] [PubMed] [Google Scholar]
  • 10.Halsey N, Coberly J, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351:786–792. doi: 10.1016/S0140-6736(97)06532-X. [DOI] [PubMed] [Google Scholar]
  • 11.Fryatt RJ. Review of published cost-effectiveness studies on tuberculosis treatment programmes. Int J Tuberc Lung Dis. 1997;1:101–109. [PubMed] [Google Scholar]
  • 12.Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the US. Arch Intern Med. 1995;155:1595–1600. doi: 10.1001/archinte.155.15.1595. [DOI] [PubMed] [Google Scholar]
  • 13.Sawert H, Girardi E, Antonucci G, et al. Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count. Arch Int Med. 1998;158:2112–2121. doi: 10.1001/archinte.158.19.2112. [DOI] [PubMed] [Google Scholar]
  • 14.Aisu T, Raviglione MC, Pragg E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counseling and testing centre. AIDS. 1995;9:267–272. [PubMed] [Google Scholar]
  • 15.Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive program on return rates for PPD test reading in patients with HIV infection. J AIDS. 1996;11:455–459. doi: 10.1097/00042560-199604150-00005. [DOI] [PubMed] [Google Scholar]
  • 16.Malotte CK, Rhodes F, Mais KE. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792–796. doi: 10.2105/AJPH.88.5.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Geiter L. Preventive therapy for tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a Comprehensive International Approach. New York: Marcel Decker; 1993. pp. 241–248. [Google Scholar]
  • 18.American Thoracic Society/Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221–S247. doi: 10.1164/ajrccm.161.supplement_3.ats600. [DOI] [PubMed] [Google Scholar]
  • 19.Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis. 1996;15:93–104. doi: 10.1300/J069v15n01_07. [DOI] [PubMed] [Google Scholar]
  • 20.Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345:1545–1548. doi: 10.1016/S0140-6736(95)91090-5. [DOI] [PubMed] [Google Scholar]
  • 21.Nolan CM. Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection. Clin Infect Dis. 1999;29:880–887. doi: 10.1086/520453. [DOI] [PubMed] [Google Scholar]
  • 22.Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1993;32:135–135. doi: 10.1056/NEJM199404283301702. [DOI] [PubMed] [Google Scholar]
  • 23.Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus infection (HIV) in a methadone maintenance program. Ann Int Med. 1989;111:761–763. doi: 10.7326/0003-4819-111-9-761. [DOI] [PubMed] [Google Scholar]
  • 24.Centers for Disease Control and Prevention Tuberculosis prevention in drug treatment centers and correctional facilities—selected US sites, 1990–1991. MMWR Morb Mortal Wkly Rep. 1993;42:210–213. [PubMed] [Google Scholar]
  • 25.Gourevitch M, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis. 1998;2:531–540. [PubMed] [Google Scholar]
  • 26.The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection. Washington, DC: US Congress, Office of Technology Assessment; 1990. [Google Scholar]
  • 27.Perlman DC, Perkins MP, Solomon N, Kochems L, Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange. Am J Public Health. 1997;87:862–863. [PubMed] [Google Scholar]
  • 28.Paone D, Perlman DC, Perkins MP, Kochems LM, Salomon N, Jarlais DC. Organizational issues in conducting tuberculosis screening at a syringe exchange. J Subst Abuse Treat. 1998;15:229–234. doi: 10.1016/S0740-5472(97)00193-1. [DOI] [PubMed] [Google Scholar]
  • 29.Perlman DC, Salomon N, Ziluck V, Freidmann P. Tuberculosis directly observed preventive therapy for active drug users. Paper presented at: 126th Annual Meeting of the American Public Health Association. November 15–18, 1998; Washington, DC. Session 2315, p. 286.
  • 30.American Thoracic Society/Centers for Disease Control and Prevention Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376–1395. doi: 10.1164/ajrccm.161.4.16141. [DOI] [PubMed] [Google Scholar]
  • 31.Snider DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA. 1986;225:1579–1583. doi: 10.1001/jama.255.12.1579. [DOI] [PubMed] [Google Scholar]
  • 32.Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253–1258. doi: 10.1001/jama.276.15.1253. [DOI] [PubMed] [Google Scholar]
  • 33.Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172–1177. doi: 10.1001/jama.276.14.1172. [DOI] [PubMed] [Google Scholar]
  • 34.Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339–1341. doi: 10.1001/jama.276.16.1339. [DOI] [PubMed] [Google Scholar]
  • 35.Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med. 1988;4:102–109. [PubMed] [Google Scholar]
  • 36.Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the US among HIV-infected persons. Ann Intern Med. 1997;126:123–132. doi: 10.7326/0003-4819-126-2-199701150-00005. [DOI] [PubMed] [Google Scholar]
  • 37.Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;321:874–879. doi: 10.1056/NEJM199212103272401. [DOI] [PubMed] [Google Scholar]
  • 38.Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989;321:874–879. doi: 10.1056/NEJM198909283211306. [DOI] [PubMed] [Google Scholar]
  • 39.Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268:504–509. doi: 10.1001/jama.268.4.504. [DOI] [PubMed] [Google Scholar]
  • 40.Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med. 1993;119:194–198. doi: 10.7326/0003-4819-119-3-199308010-00003. [DOI] [PubMed] [Google Scholar]
  • 41.Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med. 1997;337:315–320. doi: 10.1056/NEJM199707313370505. [DOI] [PubMed] [Google Scholar]
  • 42.Arno PS, Murray CJL, Bonuck KA, Alcabes P. The economic impact of tuberculosis in hospitals in New York City: a preliminary analysis. J Law Med Ethics. 1993;21:317–323. doi: 10.1111/j.1748-720X.1993.tb01256.x. [DOI] [PubMed] [Google Scholar]
  • 43.Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in person with HIV infection. Am J Respir Crit Care Med. 1996;153:1982–1984. doi: 10.1164/ajrccm.153.6.8665065. [DOI] [PubMed] [Google Scholar]
  • 44.Caiaffa WT, Graham NMH, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med. 1995;155:2111–2117. doi: 10.1001/archinte.155.19.2111. [DOI] [PubMed] [Google Scholar]
  • 45.Klein RS, Flanigan T, Schuman P, Smith D, Vlahov D. Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. J Allergy Clin Immunol. 1999;103:93–98. doi: 10.1016/S0091-6749(99)70531-2. [DOI] [PubMed] [Google Scholar]
  • 46.Centers for Disease Control and Prevention Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR Morb Mortal Wkly Rep. 1997;46(RR-15):1–10. [PubMed] [Google Scholar]
  • 47.Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS. 1999;13:2069–2074. doi: 10.1097/00002030-199910220-00009. [DOI] [PubMed] [Google Scholar]
  • 48.Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis. 1991;144:745–749. doi: 10.1164/ajrccm/144.4.745. [DOI] [PubMed] [Google Scholar]
  • 49.Goldstein S, Perlman DC, Salomon N. Two stage tuberculin skin testing in an HIV-infected population: a preliminary report. Mt Sinai J Med. 1994;61:337–340. [PubMed] [Google Scholar]
  • 50.Perlman DC, Hanvanich M. Prophylaxis and treatment of HIV-related tuberculosis. AIDS. 1997;11:S173–S179. doi: 10.1097/00002030-199712000-00011. [DOI] [PubMed] [Google Scholar]
  • 51.Raviglione MC, Sudre P, Reider HL, Spinaci S, Kochi A. Secular trends of tuberculosis in western Europe. Bull WHO. 1993;71:297–306. [PMC free article] [PubMed] [Google Scholar]
  • 52.Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on site primary care services in a methadone maintenance program. Public Health Rep. 1993;108:492–500. [PMC free article] [PubMed] [Google Scholar]
  • 53.Paone D, Clark J, Shi Q, Purchase D, Jarlais DC. Syringe exchange in the US, 1996: a national profile. Am J Public Health. 1999;89:43–46. doi: 10.2105/ajph.89.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Carvell AM, Hart GJ. Help-seeking and referrals in a needle exchange: a comprehensive service to injecting drug users. Br J Addict. 1990;1990(85):235–240. doi: 10.1111/j.1360-0443.1990.tb03076.x. [DOI] [PubMed] [Google Scholar]
  • 55.Heimer R, Kaplan EH, O'Keefe E, Khoshnood K, Altice F. Three years of needle exchange in New Haven: What have we learned? AIDS Public Policy J. 1994;9:59–62. [Google Scholar]
  • 56.Stancliff S, Salomon N, Perlman DC, Russell PC. Provision of influenza and pneumococcal vaccine to injection drug users at a syringe exchange. J Subst Abuse Treat. 2000;18:263–265. doi: 10.1016/S0740-5472(99)00064-1. [DOI] [PubMed] [Google Scholar]
  • 57.Nagamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chaing Rai, Thailand. AIDS. 1997;11:107–112. doi: 10.1097/00002030-199701000-00016. [DOI] [PubMed] [Google Scholar]
  • 58.Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV infected persons: a prospective cohort study. JAMA. 1995;274:143–148. doi: 10.1001/jama.274.2.143. [DOI] [PubMed] [Google Scholar]
  • 59.Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:1345–1349. doi: 10.1097/00002030-199310000-00007. [DOI] [PubMed] [Google Scholar]
  • 60.Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adult. Int J Tuberc Lung Dis. 1999;3:847–850. [PubMed] [Google Scholar]
  • 61.Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985–1991. doi: 10.1097/00002030-200009080-00015. [DOI] [PubMed] [Google Scholar]
  • 62.Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone with-drawal. N Engl J Med. 1976;294:1104–1106. doi: 10.1056/NEJM197605132942008. [DOI] [PubMed] [Google Scholar]
  • 63.Curtis R, Friedman SR, Neaigus A, et al. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep. 1994;109:319–327. [PMC free article] [PubMed] [Google Scholar]
  • 64.Marks SM, Taylor Z, Burrows NR, Qayad MG, Miller B. Hospitalization of homeless persons with tuberculosis in the US. Am J Public Health. 2000;90:435–438. doi: 10.2105/AJPH.90.3.435. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES